Method Development and Validation for Estimation of Brisoprolol Fumerate by UV Spectrometric Method using 0.01N HCl as Solvent

Authors

  • Swati S Rawat Student, Department of Pharmacy, SND College of Pharmacy, Yeola, Nashik, Maharashtra, India
  • Ganesh Dewan Student, Department of Pharmacy, SND College of Pharmacy, Yeola, Nashik, Maharashtra, India

DOI:

https://doi.org/10.37591/tdd.v9i1.1166

Keywords:

UV–Visible Spectrophotometric method, Method Development, Validation, Brisoprolol Fumerate and Regulatory Requirements for Drug Development.

Abstract

The objective of the present work is to develop a new, simple, economical, precise, sensitive, linear, accurate, rapid UV Spectrophotometeric method has been developed, solvent used 0.1 N HCl, for the estimation of Brisoprolol Fumerate bulk and pharmaceutical formulation as per ICH guidelines. Spiked Brisoprolol Fumerate arrangement was checked over UV-visible extend for its wavelength of greatest absorbance. The wavelength of most extreme absorbance for Brisoprolol Fumerate was found to be 223 nm. The relationship coefficient over the concentration extends of 10–50 µg/ml was found to be 0.997. The LOD and LOQ of Brisoprolol Fumerate was found to be 0.283 and 0.858 respectively. The method was successfully applied to Brisoprolol Fumerate in prepared formulation ands result were in good agreement with claims. Depending on the results, the given method can be successfully applied in estimation of Brisoprolol Fumerate.

References

Gupta A, Yadav V, Rawat S. An analytical approach for the determination of amoxicillin and potassium clavulanate in pharmaceutical dosage form. Drug Invention Today. 2011 Apr 1; 3 (4).

Gupta A, Yadav V, Yadav JS, Rawat S. An analytical approach of doxofylline: a review. Asian journal of pharmaceutical analysis. 2011; 1 (4): 67–70.

McDowall RD. Effective and practical risk management options for computerised system validation. The Quality Assurance Journal: The Quality Assurance Journal for Pharmaceutical, Health and Environmental Professionals. 2005 Sep; 9 (3): 196–227.

European Commission (2001) Final Version of Annex 15 to the EU Guide to Good Manufacturing Practice: Qualification and validation: 4, 1–10.

Chirag PA. Development and validation of UV spectrophotometric method for simultaneous estimation of metformin hydrochloride and alogliptin benzoate in bulk drugs and combined dosage forms. Pharma Chem. 2014; 6: 303–11.

Gupta, A., Yadav, J.S., Rawat, S., & Gandhi, M. (2011) Method Development and Hydrolytic Degradation Study of Doxofylline by RP-HPLC and LC-MS/MS, Asian J. Pharm. Ana, 1 (1), 14–18.

IS Committee. ICH harmonised tripartite guidelines. Validation of analytical procedures: methodology Q2. InProceedings of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 1996.

Indian pharmacopoeia.indian pharmacopoeia commission,Ghaziabad, volume-2,2007.page no: 576–578.

Manohar.A.potdar.pharmaceutical quality assurance.nirali prakashan,2nd edition 2010. page no: 8.1–8.108.

ICH, Q2A Validation of Analytical Procedure:Methodology International Conference on Harmonization, Geneva, October 1994, pg 1–8.

Downloads

Published

2022-05-17

Issue

Vol. 9 No. 1 (2022)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.